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Aims To explore sex-specific associations between long-term individual blood pressure (BP) patterns and risk of incident




Blood pressure was measured in 8376 women and 7670 men who attended at least two of the three population-
based Tromsø Study surveys conducted in 1986–87, 1994–95, and 2001. Participants were followed for incident
AF throughout 2013. Latent mixed modelling was used to identify long-term trajectories of systolic BP and hyper-
tension. Cox regression was used to estimate associations between the identified trajectories and incident AF.
Elevated systolic BP throughout the exposure period (1986–2001) independently and differentially increased risk of
AF in women and men. In women, having elevated systolic BP trajectories doubled AF risk compared to having per-
sistently low levels, irrespective of whether systolic BP increased, decreased, or was persistently high over time,
with hazard ratios of 1.88 (95% confidence interval 1.37–2.58), 2.32 (1.61–3.35), and 1.94 (1.28–2.94), respectively.
In men, those with elevated systolic BP that continued to increase over time had a 50% increased AF risk: 1.51
(1.09–2.10). When compared to those persistently normotensive, women developing hypertension during the ex-
posure period, and women and men with hypertension throughout the exposure period had 1.40 (1.06–1.86), 2.75
(1.99–3.80), and 1.36 (1.10–1.68) times increased risk of AF, respectively.
...................................................................................................................................................................................................
Conclusion Long-term BP and hypertension trajectories were associated with increased incidence of AF in both women and
men, but the associations were stronger in women.
                                                                                                                                                                                                                   
Keywords Blood pressure • Hypertension • Atrial fibrillation • Epidemiology • Sex • Trajectories
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia,
affecting about 9.5 million people in the European Society of
Cardiology member countries, and causing a significant
impairment in quality of life, increased risk of myocardial infarc-
tion, stroke, heart failure, and premature death.1–3 The preva-
lence of AF is increasing worldwide and anticipated to grow into
an epidemic in the coming decades as the world’s population
ages.2,4 Hypertension plays a crucial role in AF development5–8
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being the most important population-attributable risk factor re-
sponsible for 14% of all AF cases8. Hypertension is associated
with a 1.8-fold increased risk of incident AF and promotes pro-
gression from paroxysmal to permanent AF.9 However, since
hypertension is a modifiable AF risk factor, exploring longitudinal
trends in blood pressure (BP) is important. First, long-term pat-
terns of BP may reflect cumulative exposure to increased AF
risk and therefore provide additional prognostic information for
AF development. Secondly, it can potentially add to the existing
knowledge10,11 on whether decrease in BP over time and hyper-
tension management could reverse the risk of AF development.
The Framingham Heart Study demonstrated that both persistently
elevated systolic BP and longer antihypertensive treatment were
associated with increased risk of incident AF.12 However, the associa-
tions between BP and AF risk may differ in women and men as there
are substantial sex differences in AF epidemiology as well as in inci-
dence and types of hypertension with aging.13–16 Prevalence of AF is
almost twice as high in men as in women,14 while risk of adverse out-
comes after AF onset is higher in women.13,15 In subjects over
60 years of age, hypertension, in particular isolated systolic hyperten-
sion, is more prevalent in women.16 Furthermore, women with AF
are older and have a more favourable risk factor profile including
lower body mass index, lower proportion of diabetes, myocardial in-
farction, and smoking compared to their male counterparts, except
for higher BP.14
In the present study, we aimed to explore sex-specific long-term
individual patterns of systolic BP, diastolic BP, hypertension, and use
of antihypertensive medications and their associations with the risk
of incident AF using data from the population-based longitudinal
Tromsø Study.
Methods
Study design and participants
The Tromsø Study is a large population-based longitudinal cohort study
that has been described in detail previously.17 In short, seven consecutive
surveys of the same general design were conducted in the municipality of
Tromsø, Northern Norway between 1974 and 2016. Both random sam-
ples and total birth cohorts of women and men of a wide age range were
invited to participate, and many of the participants attended several sur-
veys. The present study included participants who attended at least two
of the Tromsø 3 (1986–87), Tromsø 4 (1994–95), and Tromsø 5 (2001)
surveys, had complete data on BP and antihypertensive treatment, were
not pregnant at examinations, had sufficient information for AF validation,
and were free of AF at the time of study examinations (Figure 1). After
the last survey attended and until 31st December 2013, 8376 women and
7670 men were followed up for incident AF. The study flow and number
of participants attended different surveys is depicted in Figure 2.
The Tromsø Study has been performed in accordance with the 1964
Declaration of Helsinki and its later amendments and approved by the
Norwegian Data Protection Authority (14/01463-8/CGN) and by the
Regional Committee for Medical and Health Research Ethics, (2009/
2536/REC North). From the Tromsø 4 survey and onwards, participants
provided written informed consent, and living participants from prior sur-
veys were provided the opportunity to withdraw from the study.
Measurement of blood pressure and other
cardiovascular risk factors
Information on each participant at each survey was collected by question-
naires, physical examinations, and blood samples, following a standardized
protocol. Systolic and diastolic BP, and heart rate were measured using
Dinamap Vital Signs Monitor 1846 (Critikon Inc., Tampa, FL, USA) which
is a non-invasive, microprocessor-controlled device, and uses the oscillo-
metric method. The proper cuff size was selected based on the circum-
ference of the upper right arm in the individual participant. After 2 min
seated rest with the cuff on, three measurements of systolic BP, diastolic
BP, and heart rate were recorded with 1-min intervals. The mean of the
last two measurements was taken as the clinic BP and used in the analy-
ses. Hypertension was defined as systolic BP >_ 140 mmHg, and/or diastol-
ic BP >_ 90 mmHg, and/or current use of antihypertensive medications.
Information on current use of antihypertensive medications (yes/no),
leisure time physical activity level (inactive/low activity/moderate activity/
high activity), current smoking (yes/no), current pregnancy (yes/no), cof-
fee consumption (cups per day), and comorbidities (diabetes, angina pec-
toris, history of myocardial infarction, and history of stroke; yes/no) was
obtained from the questionnaires. Weight and height were measured
with light clothing on, but without shoes, and were used to calculate
body mass index as weight (kg) divided by squared height (m). Non-
fasting blood samples were collected for analyses of serum levels of total
cholesterol, high density lipoprotein (HDL) cholesterol, and triglycerides.
Total cholesterol and triglycerides were analysed by enzymatic colori-
metric methods with commercially available kits (CHOD-PAP for choles-
terol, GPO-PAP for triglycerides; Boehringer-Mannheim). High
density lipoprotein-cholesterol was measured after the precipitation of
17 543 with complete data on 
blood pressure and 
anhypertensive medicaons 
17 652 aended at least two of the 
three surveys 
32 741 aended at least one of the 
three surveys 
17 232 aer exclusion of pregnant 
women 
16 343 had sufficient informaon 
for atrial fibrillaon diagnosis 
16 046 had no atrial fibrillaon at 
the start of follow-up. Of them: 
- 11 346 aended two surveys 
- 4700 aended three surveys 
Figure 1 Flowchart of participants. The Tromsø Study 1986–
2001.
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..lower-density lipoprotein with heparin and manganese chloride.
Echocardiography was performed on a subgroup of the participants in
the Tromsø 4 and 5 surveys.18
Documentation of incident atrial fibrillation
Using the unique Norwegian national 11-digit identification number, all
participants were linked to the diagnosis registry at the University
Hospital of North Norway which is the only hospital in the area and
includes diagnoses from the out- and inpatient clinic, and to the
Norwegian Cause of Death Registry.19 Possible cases of incident AF were
identified through a broad search using the International Classification of
Diseases, 9th Revision (ICD-9) codes 410–414, 427, 428, 430–438, and
798–799 and the ICD-10 codes I20–I25, I46–I48, I50, I60–I69, R96, R98,
and R99. Following a detailed protocol and based on data from hospital
and out-of-hospital records, an independent endpoint committee vali-
dated all possible events that were identified through the broad search.
Atrial fibrillation was considered as confirmed when documented by elec-
trocardiogram. We excluded 899 participants in whom AF was suspected
(terms such as arrhythmia, tachycardia, palpitations, atrial flutter, and/or
AF were mentioned in their medical records), but no electrocardiograph-
ic documentation for AF could be found (Figure 1). Transient AF occur-
ring within 28 days after acute myocardial infarction or in relation to
cardiac surgery, as well as AF occurring during the last 7 days of life were
not classified as AF cases. Participants who died or emigrated from
Tromsø during the follow-up period were identified through the
National Registry.
Statistical analyses
All statistical analyses were sex-specific and performed using SAS 9.4
(SAS Institute, Cary, NC, USA). Sex-specific means (standard deviations)
and numbers (percentages) were calculated to describe baseline charac-
teristics of the study population, measured at the first attended survey, in
1986–87 or 1994–95. Mean values (except for age) and percentages
were adjusted for age using linear or logistic regression, respectively.
Mean values for left atrial diameter/body surface area (cm/m2), left ven-
tricular mass/height2.7 (g/m2.7), left ventricular mass/height1.7 (g/m1.7), and
left ventricular ejection fraction (%), and proportions of left ventricular
hypertrophy (left ventricular mass/height2.7 > 47 g/m2.7 in women and
> 50 g/m2.7 in men) were adjusted for year of birth using linear mixed
models or generalised estimating equations, respectively.5 Trajectory ana-
lysis (SAS Proc Traj) was used to determine clusters of participants who
followed similar long-term patterns (trajectories) of systolic BP, diastolic
BP, hypertension, and use of antihypertensive medications over the ex-
posure period (from 1986 to 2001). Trajectory analysis, or latent class
models analysis, is based on a semiparametric group-based modelling
strategy and fits longitudinal data to a number of discrete latent trajecto-
ries via maximum likelihood.20 The number of trajectory groups was lim-
ited to five for BP variables, and to three for hypertension and use of
antihypertensive medications. We first tested models with different num-
bers of trajectory groups, and then models with different functional forms
of trajectory groups (only intercept, linear term, quadratic term). The
Bayesian information criterion was used to assess the model fit.
Cox regression analysis was used to estimate associations between
belonging to a certain trajectory group of systolic BP, diastolic BP, hyper-
tension, and use of antihypertensive medications and the risk of incident
AF. For each of the participants the follow-up period started at a time of
the last attended survey (1994–95 or 2001) and ended the date of first
documented AF, the date of censoring due to migration or death, or the
end of the follow-up period at 31st December 2013, whichever came
first. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calcu-
lated for the trajectory groups with the most favourable trajectory (hav-
ing the lowest BP, being free of hypertension, or not using
antihypertensive medications throughout the exposure period) used as a
reference. Hazard ratios were first adjusted for baseline age alone, and
then for baseline age, resting heart rate, total cholesterol, HDL choles-
terol, triglycerides, body mass index, leisure time physical activity level,
smoking status, and number of the Tromsø Study surveys attended.
Sensitivity analysis was conducted with adding to the models other po-
tential confounders/mediating factors for the association between the
trajectory groups and AF (coffee consumption, diabetes, angina, history
of myocardial infarction, and stroke).
Results
At baseline, systolic BP, diastolic BP, and prevalence of hypertension
were higher in men, while the proportion of participants using antihyper-
tensive medications was higher in women (Table 1). Women had lower
body mass index, more favourable blood lipid profile, and reported lower
physically activity level compared to men. The proportion of smokers did
not differ between women and men and exceeded 40%. During a median
follow-up of 12.9 years, 441 (5.3%) women and 619 (8.1%) of men devel-
oped AF (Figure 2).
Five common long-term systolic BP trajectories were identified both in
women and men (Figure 3, Supplementary material online, Figure S1).
Based on BP level at the beginning of the exposure period the trajectory
groups were numbered from the lowest (Group 1) to the highest
(Group 5). In women, mean systolic BP in Group 1 was within the
normotensive range throughout the exposure period. Group 2 was
normotensive in the beginning, but then mean systolic BP increased and
crossed the cut-off value of 140 mmHg by the end of the exposure
period. Groups 3, 4, and 5 were hypertensive throughout, though in
                               Exposure period                                               Follow-up period 





1613 emigrated 1523 died 1060 AF cases 
Parcipaon in the surveys 
 -   baseline survey 
2013 
Figure 2 Description of the exposure and the follow-up periods of the study. The Tromsø Study 1986–2013.
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..Group 3 mean systolic BP increased, in Group 4 it decreased, and in
Group 5 it remained high throughout the exposure period. In men,
Groups 1 and 2 were normotensive throughout the exposure period, al-
though in Group 2 mean systolic BP values were slightly higher. Groups
3, 4, and 5 were hypertensive. In Group 3 mean systolic BP increased
slightly, in Group 4 mean systolic BP increased substantially, and in Group
5 mean systolic BP decreased substantially during the exposure period. In
both age-adjusted and multivariable-adjusted models, the risk of incident
AF was approximately doubled in Groups 3, 4, and 5 in women, and ap-
proximately 1.5 times increased in trajectory Groups 3 and 4 in men, as
compared to Group 1 (Table 2).
Five diastolic BP trajectory groups were identified in women and men
(Figure 4, Supplementary material online, Figure S2). In both women and
men, mean diastolic BP in Groups 1 and 2 remained within the normoten-
sive range, and in Group 3 mean diastolic BP was around 90 mmHg
throughout the exposure period. Groups 4 and 5 had elevated mean dia-
stolic BP throughout the exposure period, although mean diastolic BP in
Group 4 increased and in Group 5 decreased over time. Displaying dia-
stolic BP patterns classified as Groups 3, 4, or 5 in women and classified
as Groups 4 or 5 in men progressively increased risk of developing AF
when compared to Group 1 in both age- and multivariable-adjusted anal-
yses (Table 2).
For presence or absence of hypertension at each of the three surveys,
three trajectory groups were identified in both sexes (Figure 5): normo-
tensive participants throughout (Group 1), participants who were
normotensive at the beginning, but developed hypertension during the
exposure period (Group 2), and participants who had hypertension
throughout (Group 3). In women, the risk of AF was 1.40 (95% CI 1.06–
1.86) and 2.75 (95% CI 1.99–3.80) times increased in Group 2 and Group
3, respectively, compared to Group 1. In men, only being hypertensive
throughout the exposure period increased risk of future AF with
multivariable-adjusted HR of 1.36, 95% CI 1.10–1.68 (Table 2). Three tra-
jectory groups were identified for use of antihypertensive medications at
each of the surveys during the exposure period (Figure 6). Participants
who started to use antihypertensive medications during the exposure
period (Group 2) or who used antihypertensive medications throughout
(Group 3) had gradually increased risk of developing AF in both women
and men (Table 2).
Over the exposure period, left atrial diameter, left ventricular mass,
and proportion of left ventricular hypertrophy increased gradually from
the lowest to the highest systolic BP trajectory group in both sexes
(Supplementary material online, Table S1). Left ventricular ejection frac-
tion remained stable over time in all systolic BP trajectory groups except
Groups 1 and 4 in women where it increased. Proportion of women and
men using antihypertensive medications increased during the exposure
period in all systolic BP, diastolic BP, and hypertension trajectory groups,
except for those without hypertension throughout (Supplementary ma-
terial online, Table S2). In both women and men who reported use of anti-
hypertensive medications, BP was not properly controlled: mean systolic
and diastolic BP values in antihypertensive medication trajectory Groups
2 and 3 were often above the cut-off values of 140 mmHg and 90 mmHg,
respectively (Supplementary material online, Table S3). Interaction terms
between sex and the trajectory groups were statistically significant for
systolic BP (P < 0.001), hypertension (P < 0.001), and use of antihyperten-
sive medications (P = 0.008), but not for diastolic BP (P = 0.320).
Discussion
Hypertension is an important modifiable risk factor for AF, and both
daytime BP load and long-term BP changes have been reported to be
associated with AF risk in the general population.12,21–23 The present
findings add to this by demonstrating differential associations be-
tween long-term patterns/trajectories of systolic BP, diastolic BP,
hypertension, and use of antihypertensive medications and AF risk in
....................................................................................................................................................................................................................
Table 1 Baseline sample characteristics of women and men. The Tromsø Study 1986–95.
Characteristics Women (n 5 8376) Men (n 5 7670) P-value
Age (years) 40.2 (12.0) 40.7 (13.0) 0.015
Systolic blood pressure (mmHg) 125.6 (18.0) 133.2 (14.5) <0.001
Diastolic blood pressure (mmHg) 75.4 (10.8) 78.4 (10.8) <0.001
Resting heart rate (b.p.m.) 77.3 (12.4) 72.2 (12.6) <0.001
Hypertensiona (%) 1693 (15.7) 2353 (27.8) <0.001
Use of antihypertensive medications (%) 310 (1.6) 230 (1.5) <0.001
Body mass index (kg/m2) 23.5 (3.7) 24.7 (3.0) <0.001
Serum total cholesterol (mmol/L) 5.79 (1.33) 5.90 (1.24) <0.001
Serum HDL cholesterol (mmol/L) 1.64 (0.38) 1.36 (0.34) <0.001
Serum triglycerides (mmol/L) 1.18 (0.69) 1.63 (1.01) <0.001
Leisure time physical activity level (%)
Inactive 1816 (21.8) 1577 (20.6) 0.062
Low activity 5280 (63.2) 3783 (49.4) <0.001
Moderate activity 1154 (13.5) 1965 (25.4) <0.001
High activity 104 (1.1) 336 (3.9) <0.001
Smoking (%) 3613 (43.3) 3347 (43.6) 0.715
Values are mean (standard deviation) or number (%); the means (except age) and percentages are adjusted for age between sexes using linear or logistic regression, respective-
ly. Due to missing observations, numbers (n) for the variables may be marginally less.
b.p.m., beats per minute; HDL, high-density lipoprotein; mmHg, millimetres of mercury; mmol/L, millimoles per litre.
aHypertension was defined as systolic blood pressure >_ 140 mmHg, and/or diastolic blood pressure >_ 90 mmHg, and/or current use of antihypertensive medications.
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.women and men. Although both women and men with long-term
elevated levels of systolic and diastolic BP had increased risk of future
AF development, the associations were stronger in women.
Moreover, shorter exposure to hypertension resulted in higher AF
risk in women compared to men.
Our findings add new information to the existing knowledge base
about risk factors and prevention of AF as they demonstrate that
effects of elevated BP levels and hypertension may take years to ap-
pear and that analysing long-term exposure to risk factors can im-
prove the prediction of AF compared to single time point
measurements. For example, in our study women in the systolic BP
trajectory Groups 2 (BP means increased from 129 mmHg to
144 mmHg) and 4 (BP means decreased from 160 mmHg to
146 mmHg) had similar, slightly elevated systolic BP by the end of the
exposure period. Therefore, these women would have the same sys-
tolic BP if measured only once at the end of the exposure period
(144 mmHg in Group 2 and 146 mmHg in Group 4). However,
Group 2 was normotensive during most of the exposure period,
while Group 4 had substantially elevated systolic BP levels through-
out. As demonstrated, these groups were at different risk of incident
AF: adjusted HRs were 1.12 (0.84–1.48) for Group 2 and 2.32 (1.61–
3.35) for Group 4. In comparison, our study demonstrated that men
with substantially elevated systolic BP in whom BP decreased some-
what over the exposure period (Group 5) were not at increased AF
risk, probably reflecting the low number of men in this group. The as-
sociation between hypertension and an increased risk of AF has been
demonstrated previously.6–9 Not only elevated BP but also upper
normal BP levels have been shown to increase future risk of AF.24,25
Moreover, the degree to which BP in hypertensive patients is con-
trolled provides important prognostic information in respect to fu-
ture AF development.11,26 However, there is limited evidence on
how long-term changes in BP affect AF risk in men and women in the
general population. The Malmö Preventive Project cohort demon-
strated that annual increase in both systolic and diastolic BP in men
adjusted for baseline BP increased the risk of incident AF by 4% per
mmHg and 6% per mmHg, respectively.22 However, BP changes
were calculated as differences between two BP measurements sepa-
rated by an average of 6 years, which does not describe actual individ-
ual patterns of BP changes over time.
The Framingham Heart Study explored 16-year trajectories of BP,
hypertension, and antihypertensive treatment and their associations
with the risk of AF in 4351 participants.12 The risk of AF was doubled
in participants who had initially elevated levels of systolic BP and then
either decreased or increased systolic BP. The present analysis adds
to this by demonstrating sex-differences in the systolic BP trajectories
and the stronger associations with incident AF in women than in
men. In contrast to our findings, diastolic BP trajectories in the
Framingham Heart Study were not an independent predictor of
AF.12 However, the Framingham Heart Study cohort was older than
ours, and the authors mentioned that their findings might be limited
given that four of the five diastolic BP trajectory groups had diastolic
BP lower than 90 mmHg throughout the trajectory phase. Indeed,
our findings for men demonstrate that only participants with elevated









































Group 1 (n=4662) Group 2 (n=2500) Group 3 (n=726)
























Group 1 (n=2497) Group 2 (n=3627) Group 3 (n=1167)
Group 4 (n=288) Group5 (n=91)
Figure 3 Long-term trajectory groups for systolic blood pressure in women and men. The Tromsø Study 1986–2001. Sex-specific means and
95% confidence intervals of systolic blood pressure (mmHg) presented according the three surveys and the five systolic blood pressure trajectory
groups.







niversity library of Trom



































independently increased risk of AF. In women, these associations
were stronger, and even women with borderline normal diastolic BP
values over time had increased risk of AF, pointing to the importance
of uncontrolled BP for heart disease in women. We also found stron-
ger association between hypertension trajectories and risk of AF in
women than in men.
The Atherosclerosis Risk in Communities (ARIC) Study was lim-
ited to systolic BP and hypertension and demonstrated different
long-term patterns of the parameters in men and women com-
bined.21 Systolic BP trajectories with borderline, high long-term and
very high long-term BP values progressively increased risk of AF
when compared to the very low stable trajectory.
Previous studies have demonstrated that chronic exposure to high
BP levels leads to left ventricular remodelling and impaired ventricu-
lar filling, left atrial enlargement, atherosclerosis development and ar-
terial stiffness.5,9,27–31 Dilatation of the left atria predisposes to AF
development, which may be reduced by treatment with angiotensin
receptor blocker.31,32 Structural and functional changes in the heart
may therefore mediate the effect of long-term trajectories of BP and
hypertension on the risk of AF. It has been also demonstrated that
hypertensive women compared to men are more at risk for
development of left ventricular hypertrophy and atrial dilatation,
both strong AF risk factors, and regression of left ventricular hyper-
trophy is more difficult to obtain in women despite antihypertensive
treatment.33,34 Moreover, the general lower cardiovascular risk in
women was offset in hypertension with left ventricular hyper-
trophy.30 It may therefore explain the identified sex differences and
stronger associations between BP trajectories and incident AF in
women demonstrated by the present results.
Our findings have implications for both clinical practice and public
health actions. Compared to single BP measurements, long-term pat-
terns in BP levels assess cumulative exposure and therefore provide
more information for AF risk stratification. Moreover, taking into ac-
count the cumulative effect of the exposure to elevated BP, early de-
tection and long-term management of hypertension are important to
prevent structural changes in the myocardium and thus contribute to
the prevention of AF. Although we found progressively increased AF
risk in those using antihypertensive medications over a longer period,
it could be just an approximation of hypertension status. All partici-
pants who reported use of antihypertensive medications were
included irrespective of whether treatment was effective or not, and
whether BP was controlled or not. Although at all ages, the
................................................................................ ..................................................................................
....................................................................................................................................................................................................................
Table 2 Sex-specific hazard ratios (95% confidence intervals) of incident atrial fibrillation by systolic blood pressure,
diastolic blood pressure, hypertension, and antihypertensive medications use trajectory groups. The Tromsø Study
1986–2013.
Trajectory groups Women (n 5 8376) Men (n 5 7670)
Cases/Total HR (95% CI)e HR (95% CI)f Cases/Total HR (95% CI)e HR (95% CI)f
Systolic blood pressurea
1 96/4662 1.00 1.00 132/2497 1.00 1.00
2 139/2500 1.26 (0.96–1.66) 1.12 (0.84–1.48) 236/3627 0.98 (0.79–1.22) 0.93 (0.74–1.15)
3 104/726 2.03 (1.49–2.77) 1.88 (1.37–2.58) 179/1167 1.54 (1.22–1.95) 1.41 (1.11–1.80)
4 60/321 2.76 (1.95–3.92) 2.32 (1.61–3.35) 56/288 1.60 (1.16–2.22) 1.51 (1.09–2.10)
5 42/167 2.21 (1.48–3.31) 1.94 (1.28–2.94) 16/91 1.12 (0.66–1.90) 1.10 (0.64–1.89)
Diastolic blood pressureb
1 53/1970 1.00 1.00 73/1520 1.00 1.00
2 153/4070 1.07 (0.78–1.46) 0.99 (0.72–1.37) 282/4184 0.90 (0.69–1.16) 0.86 (0.66–1.12)
3 157/1871 1.60 (1.17–2.20) 1.50 (1.08–2.08) 191/1605 1.29 (0.98–1.70) 1.20 (0.91–1.60)
4 35/195 2.12 (1.37–3.27) 1.98 (1.27–3.08) 44/231 1.75 (1.20–2.56) 1.69 (1.14–2.51)
5 43/270 2.16 (1.44–3.24) 1.87 (1.21–2.88) 29/130 2.35 (1.52–3.62) 2.14 (1.36–3.36)
Hypertensionc
1 98/5240 1.00 1.00 188/3884 1.00 1.00
2 256/2322 1.51 (1.15–1.99) 1.40 (1.06–1.86) 171/1986 1.19 (0.96–1.47) 1.10 (0.89–1.36)
3 87/814 3.18 (2.38–4.25) 2.75 (1.99–3.80) 260/1800 1.46 (1.19–1.80) 1.36 (1.10–1.68)
Antihypertensive medications used
1 257/7451 1.00 1.00 439/6881 1.00 1.00
2 80/477 1.98 (1.52–2.57) 1.75 (1.34–2.28) 83/348 1.79 (1.41–2.29) 1.62 (1.26–2.07)
3 104/448 2.79 (2.19–3.54) 2.44 (1.89–3.16) 97/441 2.03 (1.62–2.54) 1.83 (1.45–2.30)
CI, confidence interval; HDL, high-density lipoprotein; HR, hazard ratio.
aSystolic blood pressure trajectory groups are presented in Figure 3.
bDiastolic blood pressure trajectory groups are presented in Figure 4.
cHypertension trajectory groups are presented in Figure 5.
dAntihypertensive medications use trajectory groups are presented on Figure 6.
eHR (95% CI) are adjusted for age at baseline.
fHR (95% CI) are adjusted for baseline age, resting heart rate, body mass index, total cholesterol, HDL cholesterol, triglycerides, leisure time physical activity level, smoking, and
number of the Tromsø Study surveys attended.
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Group 1 (n=1970) Group 2 (n=4070) Group 3 (n=1871)






















Group 1 (n=1520) Group 2 (n=4184) Group 3 (n=1605)
Group 4 (n=231) Group5 (n=130)
Figure 4 Long-term trajectory groups for diastolic blood pressure in women and men. The Tromsø Study 1986–2001. Sex-specific means and






































Group 1 (n=3884) Group 2 (n=1986) Group 3 (n=1800)
Figure 5 Long-term trajectory groups for hypertension in women and men. The Tromsø Study 1986–2001. Sex-specific proportions of those
with hypertension presented according the three surveys and the three hypertension trajectory groups.
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prevalence and incidence of AF is higher in men than in women,4
early actions on BP management and control seem to be especially
important for women as we found stronger associations between
long-term BP trajectories and AF in women than in men.
This large population-based longitudinal study with several obser-
vations per subject and a long follow-up provides an unique oppor-
tunity to explore associations between long-term individual patterns
in BP, hypertension, use of antihypertensive medications, and the risk
of incident AF separately in women and men. Blood pressure read-
ings throughout the surveys were obtained with conventional office
BP measurement conducted by trained personal using calibrated
automated sphygmomanometers and following the same protocol.
All AF events were confirmed on electrocardiogram and validated.
However, several limitations require comments. First, although con-
ventional office BP measurement has been considered the standard
measure of an individual’s BP status and the basis for most epidemio-
logical studies, other BP measurement techniques, such as out-of-
office BP monitoring, provide readings that are more representative
for daily life and enable diagnosis of white-coat and masked hyperten-
sion.5 However, there is no evidence suggesting that using other BP
measurement techniques would change profiles/shapes of the BP tra-
jectories. Of note, mean office BP recorded in research settings has
been shown to be 10/7 mmHg lower than office BP measured in rou-
tine clinical practice.35 This difference must be considered when it
comes to the clinical implications of our findings. Second, over the
16 years of follow-up BP was measured at three time points.
Although four or five BP measurements would allow estimating
more complex cubic or quadratic trends providing more detailed
long-term BP patterns, three time points has been reported to be
enough for proper estimation of developmental trajectories.36
Besides, numerous repeated measurements usually result in greater
attrition rates that weaken statistical precision and potentially intro-
duce bias. Third, many of the study participants attended only two of
the three surveys limiting the possibility to check whether altering
the trajectories would alter outcomes, potentially reducing the ro-
bustness of the trajectory analyses, and introducing some between-
group bias. However, the associations between trajectory groups
and AF risk were adjusted for the number of attended surveys per
subject. Fourth, we lacked detailed information on antihypertensive
treatment, such as type of drugs or doses. Moreover, information on
use of antihypertensive medications as well as on physical activity and
smoking was self-reported which might introduce information bias.
However, in a cohort study such as ours, this bias would result in
non-differential misclassification.
Fifth, sample attrition that is a methodological problem in longitu-
dinal studies might result in a study population that is not entirely rep-
resentative of the general population. Participants with adverse
cardiovascular profile, including hypertension, might have died before
the next survey, therefore our study sample may over-represent
those who live longer and have healthier cardiovascular profiles. This
may lead to underestimation of the associations between BP trajecto-
ries and AF risk. Additionally, in spite of thorough ascertainment, ad-
judication and validation of AF cases it is possible that there were
participants with undiagnosed AF. Atrial fibrillation may be silent and/
or paroxysmal, and such subjects may fail to get their arrhythmia
documented on an electrocardiogram.37 Moreover, only participants
who had contact with the hospital were considered in the AF ascer-
tainment process, and some AF patients might have been taken care
of by their general practitioner without hospital contact. The associa-


















































Group 1 (n=6881) Group 2 (n=348) Group 3 (n=441)
Figure 6 Long-term trajectory groups for use of antihypertensive medications in women and men. The Tromsø Study 1986–2001. Sex-specific
proportions of those using antihypertensive medications presented according the three surveys and the three antihypertensive medication trajectory
groups.
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such as echocardiographic parameters, markers of inflammation, glu-
cose intolerance, depression, or caffeine intake. Echocardiography
was only performed in 15.4% of the participants, and we therefore
did not have statistical power to include left atrial diameter and left
ventricular hypertrophy in the models. Moreover, recent studies in
stroke survivors suggest that left atrial strain may add independent
and incremental value to the current risk-prediction models.38,39 As
our study does not include data on precise left atrial volume and
strain, it remains to be evaluated to what extent BP trajectories still
add information on top of these contemporary techniques for pre-
dicting AF. However, in the real world context, most subjects with
hypertension are not referred to echocardiography. Thus, the pre-
sent findings are highly relevant to clinical practice. Finally, caffeine
has been shown to elevate BP and independently predict risk of AF.40
However, additional adjustment for coffee consumption, diabetes,
angina pectoris, history of myocardial infarction, and history of stroke
in a sensitivity analysis had virtually no effect on the results.
Conclusion
This population-based longitudinal study identified sex-specific long-
term individual trajectories of systolic BP, diastolic BP, hypertension,
and use of antihypertensive medications. The identified long-term
trajectories that reflect cumulative exposure to the risk factors were
associated with differential risk of incident AF in women and men
(Take home figure). The associations were stronger in women where
long-term elevated systolic BP, and both elevated and borderline
normal diastolic BP were associated with increased AF risk. In men,
risk of AF was increased to a smaller extent and only in the elevated
BP trajectories. Moreover, shorter exposure to hypertension
resulted in increased AF risk in women. Our findings provide add-
itional knowledge for sex-specific AF risk stratification and primary
prevention with clinical and public health relevance.
Supplementary material
Supplementary material is available at European Heart Journal online.
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